Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 9/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202341 | 0.92 | AR (0.41) | AR | |
| SCHEMBL204604 | 0.92 | AR (0.48) | ARCYP2C19 | |
| SCHEMBL203501 | 0.90 | AR (0.43) | ARBLM | |
| SCHEMBL204278 | 0.90 | AR (0.43) | ARCYP2C19 | |
| SCHEMBL13986514 | 0.89 | AR (0.48) | ARCYP2C19 | |
| SCHEMBL202338 | 0.89 | ALDH1A1 (0.47) | PLA2G7 | |
| SCHEMBL202207 | 0.88 | AR (0.45) | AR | |
| SCHEMBL203430 | 0.87 | AR (0.42) | ARCYP2C19 | |
| SCHEMBL202639 | 0.86 | MAPT (0.46) | — | |
| SCHEMBL205016 | 0.86 | AR (0.43) | PLA2G7ARCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073626-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-07-15 | — | — | US | disclosed |
| WO-2021097046-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-11-19 | — | — | US | disclosed |
| EP-1817292-B1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-08 | — | — | EP | disclosed |
| US-8097730-B2 | Bicyclic heterocycles useful as selective androgen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-17 | — | — | US | disclosed |
| EP-1991549-B1 | BICYCLIC IMIDAZOLE OR THIADIAZOLE HETEROCYCLES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-11 | — | — | EP | disclosed |
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-8088811-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-01-03 | — | — | US | disclosed |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2010-10-21 | — | — | US | disclosed |
| US-7781473-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMS) | J & J Pharmaceutical Research & Development, LLC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | ZHANG XUQING | 2009-05-21 | — | — | US | disclosed |
| US-7465809-B2 | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) | JANSSEN PHARMACEUTICA N.V. (BG) | 2008-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131365-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | PLA2G7 2309/4885AR 1/4885BLM 4159/4885 |
| US-20210214316-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PLA2G7 3669/4885AR 9/4885BLM 2097/4885 |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PLA2G7 3669/4885AR 9/4885BLM 2097/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PLA2G7 3669/4885AR 9/4885BLM 2097/4885 |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PLA2G7 3669/4885AR 9/4885BLM 2097/4885 |
| US-20100267670-A1 | NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, NR5A2 | PLA2G7 2309/4885AR 1/4885BLM 4159/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PLA2G7 3669/4885AR 9/4885BLM 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.